Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Joaquín Gavilá,Mafalda Oliveira,T Pascual,Jose Perez-Garcia,X. Gonzalez,J Canes,Laia Paré,Isabel Romero-Calvo,Eva Ciruelos,Montserrat Muñoz,Juan Antonio Virizuela,Isabel Ruiz,Raquel Andres,A. Perelló,Jerónimo Martínez,Serafin Morales,Mercedes Marín-Aguilera,D Martínez,Juan C. Quero,Antonio Llombart-Cussac,Aleix Prat

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

2019

Background The Opti-HER HEART trial aimed to optimize activity while minimizing cardiac risk by combining trastuzumab, pertuzumab, and paclitaxel with non-pegylated liposomal doxorubicin in the treatment of HER2-positive early breast cancer.

Keywords:

Breast cancer
Pegylated Liposomal Doxorubicin
Physical therapy
HER2 Positive Breast Cancer
Oncology
Trastuzumab
Paclitaxel/trastuzumab
Paclitaxel
Pertuzumab
Medicine
Liposomal Doxorubicin
Internal medicine
Ejection fraction
Neoadjuvant therapy
Clinical endpoint
Odds ratio

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations